Abel De La Rosa

Abel De La Rosa, Ph.D, of Port St. Joe, co-founded Antios Therapeutics and served as CEO and Director, later transitioning to Chairman of the Board and Scientific & Strategic Advisor. Prior to Antios, he was Chief Scientific Officer of the Drug Innovation Ventures at Emory (DRIVE) and the Emory Institute for Drug Development (EIDD) at Emory University, focused on the discovery and development of antiviral drugs for the treatment of viral diseases of unmet medical need and global concern. While at Emory University, he was an inventor on technologies licensed to pharmaceutical and biotechnology companies.

Prior to joining Emory University, Dr. De La Rosa was Senior Vice President of Business Development & Scientific Affairs with Pharmasset. He provided business and scientific leadership to drug development programs for the treatment of infectious diseases, including Sofosbuvir for the treatment of Hepatitis C. Prior to Pharmasset, Dr. De La Rosa was Vice President of Product Development at Visible Genetics, and held scientific positions at Innogenetics, Boston Biomedica, and Digene, developing molecular diagnostic tests for infectious diseases. He is an inventor and author on several U.S. patents and publications relating to molecular diagnostic methods, techniques and therapeutics for infectious diseases and cancer and has served on the Board of Directors of private and public biotechnology companies.

Dr. De La Rosa earned a Fogarty Fellowship and an Intramural Research Training Award Fellowship from the National Institutes of Health, where he completed post-doctoral training in the Laboratory of Biochemistry and the Laboratory of Pathology of the National Cancer Institute. He holds a Bachelor’s Degree in Microbiology from the University of California, San Diego, and a Ph.D. in Microbiology from Miami University.

He was appointed by Governor Ron DeSantis on December 6, 2022.